Molecule
Uridine triacetate is a pyrimidine analog indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. It is available as granules for oral use. MedsAcross supplies Uridine triacetate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
XURIDEN ® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. XURIDEN is a pyrimidine analog for uridine replacement indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria.
Source: US FDA prescribing information
Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation (Figure 1). Figure 1: Uridine Triacetate Conversion to Uridine XURIDEN provides uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis. Figure 1
Source: US FDA prescribing information
Recommended Dosage: The starting dosage is 60 mg/kg once daily, the dose may be increased to120 mg/kg (not to exceed 8 grams) once daily for insufficient efficacy. See the full prescribing information for 60 mg/kg and 120 mg/kg weight-based dosing tables. Preparation and Administration. Measure the dose using either a scale accurate to at least 0.1 gram, or a graduated teaspoon, accurate to the fraction of the dose to be administered. Administer the dose with food (applesauce, pudding or yogurt) or in milk or infant formula. See full prescribing information for preparation and administration instructions.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
None
Source: US FDA prescribing information
No adverse reactions were reported in clinical trials with XURIDEN in patients with hereditary orotic aciduria.
Source: US FDA prescribing information
Store at controlled room temperature, 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Uridine triacetate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vistogard 951 mg/g granulesOral | BTG International | US FDA | Available on request |
| Xuriden 951 mg/g granulesOral | BTG International | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 4 September 2015 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Uridine triacetate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Uridine triacetate, including Vistogard, Xuriden.
Yes. The US FDA first approved Uridine triacetate on 4 September 2015, according to Drugs@FDA.
No listed presentation of Uridine triacetate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Uridine triacetate is classified under ATC code A16AX13 (Uridine triacetate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.